Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts.
about
Lupus Nephritis: A Different Disease in European Patients?Current and emerging treatment options in the management of lupusKey issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implicationsUse of biologics in SLE: a review of the evidence from a clinical perspectiveUnmet medical needs in systemic lupus erythematosusWhat is new in the management of rapidly progressive glomerulonephritis?CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases.Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry.Prospective data collection of off-label use of rituximab in Australian public hospitals.Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study.Novel therapeutic agents in clinical development for systemic lupus erythematosus.In-/off-label use of biologic therapy in systemic lupus erythematosus.Genetics of Lupus Nephritis: Clinical Implications.Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus.Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapyUse of rituximab as a treatment for systemic lupus erythematosus: retrospective review.Ofatumumab treatment in lupus nephritis patients.Lupus nephritis in children - 10 years' experience.B-cell depletion in the treatment of lupus nephritis.Indications for use and safety of rituximab in childhood renal diseases.B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab.Rituximab treatment in lupus nephritis--where do we stand?Minimising steroids in lupus nephritis--will B cell depletion pave the way?B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.B-cell targeted therapeutics in clinical development.B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress.Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.Systemic lupus erythematosus: a therapeutic challenge for the XXI century.Update on B-cell targeted therapies for systemic lupus erythematosus.Emerging biological therapies for systemic lupus erythematosus.Rituximab and lupus--a promising pair?Biologics in systemic lupus erythematosus: current options and future perspectives.Treatment of severe lupus nephritis: the new horizon.The multifaceted aspects of refractory lupus nephritis.Current role of rituximab in systemic lupus erythematosus.Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus.Reviewing the recommendations for lupus in children.Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus.
P2860
Q26740483-6F6C2552-7A50-4B43-A294-E182C96D81E0Q26741266-7B90C8A0-AE62-400E-9751-BF34C030F584Q26775756-753B0F10-11E8-4E12-8B9A-4CDC749ACD68Q26783652-849B6D3E-EB81-4C77-8A02-B4F1425C739EQ27005906-D2A468C5-6DD2-4167-80FE-6DC267B8A353Q28259540-08182925-FCF6-4A59-A276-22C2848C2813Q30388433-9720F9C2-BE5D-41B3-80D5-D0295CCCD152Q30582614-C55D90BC-5A60-4C63-8FA6-1FA4519C984EQ30640279-991723F9-7B4E-49DC-AF61-F689A7649829Q33885872-D7E15F55-9DC1-425E-9493-82DAC3CC9D77Q34704902-BDE92479-6FF6-4CA7-9CB7-64406BEC8619Q35094536-B3E47FAB-68EF-4748-86BD-6E8199397447Q36300008-F4721E65-2E70-4FC3-9C8C-8717EC9A1586Q36302245-7D557D1F-A7D1-44C4-892A-81790E13A526Q36469965-EE963404-8749-47B4-8092-5CCBAFE82477Q36518986-220851AC-5268-4C94-AE3C-D62DB399EB58Q36981769-71E24E8C-EEDF-4AAD-9B77-1351C9B50E63Q37119045-BA0D11C3-9B18-4ED1-A769-D439C60405D3Q37399315-91109D3D-CC03-44AA-8AF8-2E177AE877C9Q38026784-250E467E-B942-48BC-A5FC-A74FFEBD56A4Q38044851-245D15AB-61AC-4A8A-8ADC-03DFEB482C97Q38051302-1EBE27CB-6BFD-4774-A07F-FD295B7C37B5Q38095863-41A24F79-8290-48B4-92EA-D7549DDE8275Q38095864-6C3B54A0-6929-4D2B-80BC-BED86147ED47Q38097129-1D63D154-FE5D-4946-95EE-24DFBC0CF25EQ38097162-0A0CB5D9-E353-48AE-8471-7B4C0AA357BBQ38131034-336DB1C2-79F7-46A6-98DD-61477A9133C9Q38150110-73FAC118-9541-40E7-B4F3-3856281C47C6Q38154934-355E8846-39BE-47D1-BAFA-C9266936C6A2Q38191835-2B861E3A-2251-440C-9FCA-1AAD5078DF6EQ38192656-7FFF3FA5-7B3D-431B-85D5-A92184576269Q38192683-DD98A675-4C85-4419-B2D0-5C3B44067F93Q38235185-8680136A-1654-4889-9008-9E9A43DEEBF3Q38238798-FEF66FA6-CA69-48AB-9E53-9AEB46D98756Q38271125-21FE350A-675A-4417-8BB4-91FBF17BC3C8Q38285375-254B0EFA-61F7-466B-A8F4-733BAF792D04Q38293284-3D3A4979-B16C-4A99-BD0F-F45219D406A4Q38306720-E60D6CCE-295C-4E05-BAFC-B40EDECB32F4Q38374309-BDABD3E2-5A4C-4A94-A4DF-4C365F33DAC9Q38389307-CF58C29E-794A-4E65-A9D2-DBA53411F03F
P2860
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Efficacy of rituximab in 164 p ...... ed data from European cohorts.
@ast
Efficacy of rituximab in 164 p ...... ed data from European cohorts.
@en
Efficacy of rituximab in 164 p ...... ed data from European cohorts.
@en-gb
Efficacy of rituximab in 164 p ...... ed data from European cohorts.
@nl
type
label
Efficacy of rituximab in 164 p ...... ed data from European cohorts.
@ast
Efficacy of rituximab in 164 p ...... ed data from European cohorts.
@en
Efficacy of rituximab in 164 p ...... ed data from European cohorts.
@en-gb
Efficacy of rituximab in 164 p ...... ed data from European cohorts.
@nl
prefLabel
Efficacy of rituximab in 164 p ...... ed data from European cohorts.
@ast
Efficacy of rituximab in 164 p ...... ed data from European cohorts.
@en
Efficacy of rituximab in 164 p ...... ed data from European cohorts.
@en-gb
Efficacy of rituximab in 164 p ...... ed data from European cohorts.
@nl
P2093
P50
P1433
P1476
Efficacy of rituximab in 164 p ...... ed data from European cohorts.
@en
P2093
Agustín Martínez-Berriotxoa
Cándido Díaz-Lagares
David D'Cruz
David Jayne
Edward M Vital
Fausta Catapano
Francisco García-Hernández
Javier Rascón
José-Luis Callejas-Rubio
Sara Croca
P304
P356
10.1016/J.AUTREV.2011.10.009
P50
P577
2011-10-18T00:00:00Z
P6179
1034872285